Bacillus coagulans (PROBACI) in treating constipation-dominant functional bowel disorders

Chen-Wang Chang, Ming-Jen Chen, Shou-Chuan Shih, Ching-Wei Chang, Jen-Shiu Chiang Chiau, Hung-Chang Lee, Yang-Sheng Lin, Wei-Chen Lin, Horng-Yuan Wang, Chen-Wang Chang, Ming-Jen Chen, Shou-Chuan Shih, Ching-Wei Chang, Jen-Shiu Chiang Chiau, Hung-Chang Lee, Yang-Sheng Lin, Wei-Chen Lin, Horng-Yuan Wang

Abstract

Bacillus coagulans (PROBACI) bacteria have been examined for efficacy against infectious or inflammatory bowel diseases. The aim of this observational and cross-sectional study was to evaluate the effects of PROBACI against various functional bowel symptoms.Thirty-eight enrolled patients (36.5 ± 12.6 years) with functional bowel disorders in a gastrointestinal clinic were administered PROBACI (300-mg formulation containing 1 × 10 colony-forming units of B coagulans) twice/day over a 4-week period. Abdominal pain, abdominal distention, and global assessment were evaluated using a 5-point visual analog scale. The defecation characteristics, discomfort level, and effort required for defecation were recorded. The gut-microbiota composition in terms of the Firmicutes/Bacteroidetes ratio was analyzed by 16S-ribosomal RNA gene sequencing with stool samples at days 0, 14, and 28 post-treatment.The 38 patients achieved significant improvements in abdominal pain (2.8 ± 0.5 to 3.3 ± 0.7, P = .0009), abdominal distention (2.5 ± 0.7 to 3.2 ± 0.8, P = .0002), and global assessment (2.7 ± 0.6 to 3.6 ± 0.7, P = .0001) from days 0 to 14. Compared with the diarrhea group, the constipation group achieved greater improvements in terms of discomfort during defecation (2.5 ± 0.7 to 3.1 ± 0.7, P = .02) and normalization of defecation style (50% vs 7.1%, P = .007) by day 28. A difference was observed in the Firmicutes/Bacteroidetes ratio between the constipation-dominant group (118.0) and diarrhea-dominant group (319.2), but this difference was not significant.PROBACI provided control of abdominal pain, less discomfort during defecation, and a more normalized defecation style, especially in the constipation-dominant group.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
(A) Abdominal pain score of the patients after treatment from day 0, day 14, and day 28 in all patients (n = 38). Significant differences were found in week 14 (P = .0009) and week 28 (P < .00001) compared with week 0 (analysis with Mann–Whitney U test). (B) Abdominal distention score of the patients after treatment from day 0, day 14, and day 28 in all patients (n = 38). Significant difference were found in week 14 (P = .0002) and week 28 (P < .00001) compared with week 0 (analysis with Mann–Whitney U test). (C) Global assessment score of the patients after treatment from day 0, day 14, and day 28 in all patients (n = 38). Significant difference were found in week 14 (P < .00001) and week 28 (P < .00001) compared with week 0 (analysis with Mann–Whitney U test).
Figure 2
Figure 2
The change of the Firmicutes/Bacteroidetes ratio during the treatment period.

References

    1. Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000;130:396S–402S.
    1. Quigley EM. The use of probiotics in functional bowel disease. Gastroenterol Clin North Am 2005;34:533–45.
    1. Mimura T, Rizzello F, Helwig U, et al. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004;53:108–14.
    1. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology 2004;126:1358–73.
    1. Greenwood-Van Meerveld B, Johnson A, Kajs T, et al. Probiotic bactet/a normalize post inflammatory visceral hyperalgesia in rats. Gastroenterology 2003;112:A476.
    1. Lamine F, Cauquil E, Eutamene H, et al. Lactobacillns farciminis treatment reduces sensitivity to rectal distension in rats: involvement of nitric oxide. Gastroenterology 2003;122:A476.
    1. Ruepert L, Quartero AO, de Wit NJ, et al. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Datab Syst Rev 2011;CD003460.
    1. Keller D, Farmer S, McCartney A, et al. Bacillus coagulans as a probiotic. Food Sci Technol Bull Funct Foods 2010;7:7.
    1. Jensen GS, Benson KF, Carter SG, et al. GanedenBC30 cell wall and metabolites: anti-inflammatory and immune modulating effects in vitro. BMC Immunol 2010;11:15.
    1. Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a synbiotic containing Bacillus Coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench 2014;7:156–63.
    1. Saneian H, Pourmoghaddas Z, Roohafza H, et al. Synbiotic containing Bacillus coagulans and fructo-oligosaccharides for functional abdominal pain in children. Gastroenterol Hepatol Bed Bench 2015;8:56–65.
    1. Guo X, Xia X, Tang R, et al. Development of a real-time PCR method for Firmicutes and Bacteroidetes in faeces and its application to quantify intestinal population of obese and lean pigs. Lett Appl Microbiol 2008;47:367–73.
    1. Gwee KA, Collins SM, Read NW, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 2003;52:523–6.
    1. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503–6.
    1. Shanahan F. Immunology Therapeutic manipulation of gut flora. Science 2000;289:1311–2.
    1. King TS, Elia M, Hunter JO. Abnormal colonic fermentation in irritable bowel syndrome. Lancet 1998;352:1187–9.
    1. Quigley EM. From comic relief to real understanding; how intestinal gas causes symptoms. Gut 2003;52:1659–61.
    1. Serra J, Azpiroz F, Malagelada JR. Impaired transit and tolerance of intestinal gas in the irritable bowel syndrome. Gut 2001;48:14–9.
    1. Jiang T, Savaiano DA. Modification of colonic fermentation by bifidobacteria and pH in vitro. Impact on lactose metabolism, short-chain fatty acid, and lactate production. Dig Dis Sci 1997;42:2370–7.
    1. Ouwehand AC, Lagstrom H, Suomalainen T, et al. Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly. Ann Nutr Metab 2002;46:159–62.
    1. Piche T, des Varannes SB, Sacher-Huvelin S, et al. Colonic fermentation influences lower esophageal sphincter function in gastroesophageal reflux disease. Gastroenterology 2003;124:894–902.
    1. Ropert A, Cherbut C, Roze C, et al. Colonic fermentation and proximal gastric tone in humans. Gastroenterology 1996;111:289–96.
    1. Minamida K, Nishimura M, Miwa K, et al. Effects of dietary fiber with Bacillus coagulans lilac-01 on bowel movement and fecal properties of healthy volunteers with a tendency for constipation. Biosci Biotechnol Biochem 2015;79:300–6.
    1. Mariat D, Firmesse O, Levenez F, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. BMC Microbiol 2009;9:123.
    1. Nyangale EP, Farmer S, Keller D, et al. Effect of prebiotics on the fecal microbiota of elderly volunteers after dietary supplementation of Bacillus coagulans GBI-30, 6086. Anaerobe 2014;30:75–81.
    1. Ley RE, Turnbaugh PJ, Klein S, et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006;444:1022–3.
    1. Soldi S, Vasileiadis S, Uggeri F, et al. Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: a molecular approach. Clin Exp Gastroenterol 2015;8:309–25.
    1. Wang A, Ling Z, Yang Z, et al. Gut microbial dysbiosis may predict diarrhea and fatigue in patients undergoing pelvic cancer radiotherapy: a pilot study. PLoS One 2015;10:e0126312.
    1. Irvine EJ, Tack J, Crowell MD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2016;150:1469–80.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa